ClinicalTrials.gov
 Home    Search    Study Topics    Glossary  
 

  Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Intrathecal Magnesium and Postoperative Analgesia

This study is currently recruiting participants.
Verified by University Hospital, Clermont-Ferrand, October 2008

Sponsors and Collaborators: University Hospital, Clermont-Ferrand
University Hospital
Information provided by: University Hospital, Clermont-Ferrand
ClinicalTrials.gov Identifier: NCT00560092
  Purpose

Magnesium is implicated in the activation of NMDA receptors by amino-excitatory acids in the central nervous system [1]. Magnesium deficiency is associated to an increased activation of these receptors, and to an increased sensitivity to pain in animals. Spinal cord is the site of sensitization of pain, mainly mediated by the NMDA receptors, and intrathecal magnesium may have anti-hyperalgesic effect when administered intrathecally [2]. As intrathecal magnesium has already been used in humans for treatment of eclampsia, we stated that it could also improve postoperative analgesia and reduce the need for auto-administered morphine if given (50 mg of magnesium sulfate) with the intrathecal anesthetic drugs (bupivacaine and sufentanil) injected for orthopedic surgery.


Condition Intervention Phase
Total Hip Replacement
Drug: intrathecal magnesium sulfate
Phase III

MedlinePlus related topics:   Anesthesia   

ChemIDplus related topics:   Magnesium    Magnesium sulfate   

U.S. FDA Resources

Study Type:   Interventional
Study Design:   Treatment, Randomized, Double Blind (Subject, Investigator), Placebo Control, Single Group Assignment, Efficacy Study
Official Title:   Effects of a Single Dose of Intrathecal Magnesium Sulfate on Postoperative Morphine Consumption After Total Hip Replacement

Further study details as provided by University Hospital, Clermont-Ferrand:

Primary Outcome Measures:
  • Reduction of morphine consumption in the postoperative period. [ Time Frame: in the postoperative period ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Duration of sensory and motor blockade induced by the intrathecal anesthesia ; side effects; postoperative pain (visual analogue scale). [ Time Frame: postoperative pain ] [ Designated as safety issue: Yes ]

Estimated Enrollment:   40
Study Start Date:   January 2004
Estimated Study Completion Date:   October 2008
Estimated Primary Completion Date:   October 2008 (Final data collection date for primary outcome measure)

Intervention Details:
    Drug: intrathecal magnesium sulfate
    intrathecal magnesium sulfate
Detailed Description:

Magnesium is implicated in the activation of NMDA receptors by amino-excitatory acids in the central nervous system [1]. Magnesium deficiency is associated to an increased activation of these receptors, and to an increased sensitivity to pain in animals. Spinal cord is the site of sensitization of pain, mainly mediated by the NMDA receptors, and intrathecal magnesium may have anti-hyperalgesic effect when administered intrathecally [2]. As intrathecal magnesium has already been used in humans for treatment of eclampsia, we stated that it could also improve postoperative analgesia and reduce the need for auto-administered morphine if given (50 mg of magnesium sulfate) with the intrathecal anesthetic drugs (bupivacaine and sufentanil) injected for orthopedic surgery.

  Eligibility
Ages Eligible for Study:   56 Years to 93 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Criteria

Inclusion Criteria:

  • Total hip replacement under intrathecal anesthesia.

Exclusion Criteria:

  • General anesthesia (alone or not)
  • Intolerance to morphine
  • Misunderstanding of the use of the device for intravenous patient-controlled administration of morphine.
  Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00560092

Contacts
Contact: Christian Duale, Doctor     (33) 04 73 751 590     cduale@chu-clermontferrand.fr    

Locations
France, Auvergne
Clermont-Ferrand University Hospital     Recruiting
      Clermont-Ferrand, Auvergne, France, 63000

Sponsors and Collaborators
University Hospital, Clermont-Ferrand
University Hospital

Investigators
Principal Investigator:     Christian Duale, Dr     University Hospital, Clermont-Ferrand    
  More Information


Publications:

Responsible Party:   CHU Clermont-Ferrand ( Dr Christian DUALE )
Study ID Numbers:   CHU63-006
First Received:   June 22, 2006
Last Updated:   October 7, 2008
ClinicalTrials.gov Identifier:   NCT00560092
Health Authority:   France: Ministry of Health

Keywords provided by University Hospital, Clermont-Ferrand:
Magnesium  
Pain  
Morphine  
Intrathecal
NMDA
Elective total hip replacement under intrathecal anesthesia

Study placed in the following topic categories:
Morphine
Magnesium Sulfate
Pain

Additional relevant MeSH terms:
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Anesthetics
Central Nervous System Depressants
Calcium Channel Blockers
Reproductive Control Agents
Cardiovascular Agents
Pharmacologic Actions
Membrane Transport Modulators
Tocolytic Agents
Sensory System Agents
Therapeutic Uses
Analgesics
Peripheral Nervous System Agents
Anti-Arrhythmia Agents
Central Nervous System Agents
Anticonvulsants

ClinicalTrials.gov processed this record on October 10, 2008




Links to all studies - primarily for crawlers